These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Zhang X; Zegar T; Weiser T; Hamdan FH; Berger BT; Lucas R; Balourdas DI; Ladigan S; Cheung PF; Liffers ST; Trajkovic-Arsic M; Scheffler B; Joerger AC; Hahn SA; Johnsen SA; Knapp S; Siveke JT Int J Cancer; 2020 Nov; 147(10):2847-2861. PubMed ID: 32599645 [TBL] [Abstract][Full Text] [Related]
7. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822 [TBL] [Abstract][Full Text] [Related]
8. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027 [TBL] [Abstract][Full Text] [Related]
9. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis. Yan Z; Ohuchida K; Fei S; Zheng B; Guan W; Feng H; Kibe S; Ando Y; Koikawa K; Abe T; Iwamoto C; Shindo K; Moriyama T; Nakata K; Miyasaka Y; Ohtsuka T; Mizumoto K; Hashizume M; Nakamura M J Exp Clin Cancer Res; 2019 May; 38(1):221. PubMed ID: 31133044 [TBL] [Abstract][Full Text] [Related]
11. Targeting of the P2X7 receptor in pancreatic cancer and stellate cells. Giannuzzo A; Saccomano M; Napp J; Ellegaard M; Alves F; Novak I Int J Cancer; 2016 Dec; 139(11):2540-52. PubMed ID: 27513892 [TBL] [Abstract][Full Text] [Related]
12. Disruption of Super-Enhancers in Activated Pancreatic Stellate Cells Facilitates Chemotherapy and Immunotherapy in Pancreatic Cancer. Wang Y; Chen K; Liu G; Du C; Cheng Z; Wei D; Li F; Li C; Yang Y; Zhao Y; Nie G Adv Sci (Weinh); 2024 Apr; 11(16):e2308637. PubMed ID: 38417121 [TBL] [Abstract][Full Text] [Related]